Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

Have you been paying attention to shares of Castle Biosciences, Inc. (CSTL) ? Shares have been on the move with the stock up 10.7% over the past month. The stock hit a new 52-week high of $34.49 in the previous session. Castle Biosciences, Inc. has gained 58.8% since the start of the year compared to the 8.6% move for the Zacks Medical sector and the -0.2% return for the Zacks Medical - Biomedical and Genetics industry. What's Driving the Outperformance? The stock has a great record of positive earnings sur ...

Castle Biosciences, Inc. (CSTL) shares ended the last trading session 9.4% higher at $34.26. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.4% gain over the past four weeks. The stock rallied as optimism grew over the company's promising portfolio that consists of tests for skin cancers, Barrett's esophagus, mental health conditions and uveal melanoma. This company is expected to post quarterly loss of $0.08 per ...

Castle Biosciences, Inc. (CSTL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Since a c ...

ManuWe Investment Thesis Castle Biosciences (NASDAQ:CSTL) is a fast-growing molecular diagnostics company that focuses on selling prognostic tests for dermatological (skin) cancer, esophageal cancer and mental health patients. Castle Biosciences has demonstrated consistently rapid revenue growth and is trading at a cheap based on a 2.1x EV/TTM GP. In Q2 2024, Castle Biosciences inflected into net income and operating profitability in Q2 2024, which should drive more institutional and retail interest and thu ...

Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR & Corporate Affairs Derek Maetzold - Founder, President and CEO Frank Stokes - CFO Conference Call Participants Catherine Schulte - Baird Mason Carrico - Stephens Thomas Flaten - Lake Street Puneet Souda - Leerink Partners Kyle Mikson - Canaccord Genuity Sung Nam - Scotiabank Subbu Nambi - Guggenheim Mark Massaro - BTIG Operator Good afternoon, and welcome to Castle ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-38984 CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Dela ...

Exhibit 99.1 Castle Biosciences Reports Second Quarter 2024 Results Q2 2024 revenue increased 74% over Q2 2023 to $87 million Q2 2024 total test reports increased 49% over Q2 2023 Raising full-year 2024 revenue guidance to $275-300 million from $255-265 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas - Aug. 5, 2024--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the s ...

Castle Biosciences, Inc. (CSTL) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released o ...

Therefore, the Zacks rating upgrade for Castle Biosciences basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. Most Powerful Force Impacting Stock Prices The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earn ...